Consumers Taking GLP-1s for Weight Loss, Current or Discontinued, Drive Lasting Changes in Retail, Per New Acosta Group Study 76% of those who discontinued GLP-1s are eating the same amount or less and many report retaining healthy habits JACKSONVILLE, Fla., April 14, 2025 /PRNewswire/ -- In advance of the National Association of Chain Drug Stores (NACDS) Annual Meeting, Acosta Group is sharing the results of its recent proprietary GLP-1 Shopper Community study, focusing on consumers using the medications specifically to support weight loss
Needle-Free Dosing Needle-Free Dosing Say goodbye to injections and hello to convenience
GLP-1s are likely here to stay
Third, oral semaglutide (Wegovy pill, $149/mo at Walgreens) entered US distribution in late 2025, giving needle-averse patients a brand-name option for the first time
IPharma collaborates with your provider to assess your eligibility, discuss treatment goals, and ensure the medication is tailored to you
These can often be managed by eating slowly, having smaller portions, and staying well hydrated